B. Riley lowered the firm’s price target on InfuSystem (INFU) to $12 from $14 and keeps a Buy rating on the shares following the Q1 report. The company remains focused on improving profitability while pursuing growth opportunities such as advanced wound care and chemo mouthpiece, the analyst tells investors in a research note. Riley expects InfuSystem to continue to repurchase shares throughout the year.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INFU:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue